Steven Davidoff Solomon writes for The New York Times, May 1, 2015
If there is no deal, shareholders are going to have to face those thorny questions: How do they measure DuPont’s performance — starting from 2007 or 2008? Include the new health and nutrition business or not? The fate of a $60 billion company may hinge on these answers.